GHK-Cu vs LL-37
Updated November 5, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of GHK-Cu and LL-37 (also searched as LL-37 vs GHK-Cu) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
GHK-Cu centers on skin, while LL-37 leans toward healing. On indexed research, LL-37 is ahead (GHK-Cu: 27 studies, Preclinical; LL-37: 34, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •GHK-Cu is strongest for skin; LL-37 for healing.
- •Evidence: GHK-Cu Preclinical (27 studies) vs LL-37 Human evidence (34).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
GHK-Cu vs LL-37: side-by-side
| Metric | GHK-Cu | LL-37 |
|---|---|---|
| Class | Healing | Immune |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Preclinical | Human evidence |
| Studies indexed | 27 | 34 |
| Research level | Preclinical | Well Studied |
| Strongest effect | Skin & aesthetics | Healing & recovery |
| Healing & recovery | 5.0▲ | 5.0▲ |
| Muscle & body comp | 1.0▲ | 0.0 |
| Metabolic & appetite | 2.0▲ | 0.0 |
| Neuro & mood | 1.0▲ | 0.0 |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 4.0▲ | 4.0▲ |
| Skin & aesthetics | 5.0▲ | 2.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | GHK-Cu | LL-37 |
|---|---|---|
| Mechanism | Copper-binding tripeptide (GHK-Cu); tissue-remodeling / regenerative signaling | Disrupts microbial membranes, modulates immune responses |
| Route | Topical / subcutaneous | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is GHK-Cu?
Copper-binding tripeptide widely used in skin, hair, and wound-healing contexts, with systemic effects explored in research.
Full GHK-Cu profile, mechanism & studies →What is LL-37?
LL-37 is a human cathelicidin antimicrobial peptide that plays a crucial role in the innate immune response. It is produced by various cells, including epithelial cells and neutrophils, and exhibits a broad spectrum of biological activities, including antimicrobial, immunomodulatory, and wound healing properties. LL-37 interacts with a variety of pathogens, including bacteria, viruses, and fungi, contributing to the host's defense mechanisms.
Full LL-37 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Even | Both ~5.0/5 |
| Muscle | GHK-Cu | 1.0/5 effect signal |
| Metabolic | GHK-Cu | 2.0/5 effect signal |
| Neuro | GHK-Cu | 1.0/5 effect signal |
| Inflammation | Even | Both ~4.0/5 |
| Skin | GHK-Cu | 5.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack GHK-Cu and LL-37?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
GHK-Cu vs LL-37: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
GHK-Cu has 27 approved studies indexed (Preclinical), and LL-37 has 34 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is GHK-Cu or LL-37 better?
It depends on your goal. GHK-Cu is strongest for skin; LL-37 for healing. LL-37 has more indexed studies (34). See the goal-by-goal breakdown above.
Is GHK-Cu or LL-37 better for weight loss?
GHK-Cu shows the stronger metabolic & appetite profile (2.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is GHK-Cu or LL-37 better for muscle?
GHK-Cu leads on the muscle & body-composition axis (1.0/5).
Which has more research, GHK-Cu or LL-37?
GHK-Cu has 27 approved studies indexed (Preclinical); LL-37 has 34 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack GHK-Cu and LL-37?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of GHK-Cu vs LL-37?
GHK-Cu: no community-reported effects logged yet. LL-37: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is GHK-Cu or LL-37 FDA-approved?
GHK-Cu is a research-use compound and is not FDA-approved. LL-37 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is LL-37 better than GHK-Cu?
For healing, LL-37 has the edge; for skin, GHK-Cu does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
GHK-Cu and LL-37 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed November 5, 2026.